SELLAS Life Sciences (SLS) Amortizatization of Intangibles (2016 - 2026)
SELLAS Life Sciences (SLS) reported Amortizatization of Intangibles of $153000.0 for Q1 2026, up 4.08% year-over-year from $147000.0 in Q1 2025, and down 0.65% quarter-over-quarter from $154000.0 in Q4 2025.
SELLAS Life Sciences (SLS) Amortizatization of Intangibles (2016 - 2026) Analysis & Trends
SELLAS Life Sciences (SLS) has 7 years of Amortizatization of Intangibles data on file, last reported at $153000.0 in Q1 2026.
- Amortizatization of Intangibles for Q1 2026 came in at $153000.0, up 4.08% year-over-year; the trailing twelve-month figure through Mar 2026 was $603000.0 (up 5.79% YoY), and the FY2025 annual result was $597000.0, up 6.42% from the prior year.
- Amortizatization of Intangibles declined to $153000.0 in Q1 2026 per SLS's latest filing, from $154000.0 in the prior quarter.
- Over five years, Amortizatization of Intangibles peaked at $207000.0 in Q3 2022 and troughed at $45000.0 in Q1 2022.
- A 5-year average of $133117.6 and a median of $138000.0 in 2024 frame the typical range for Amortizatization of Intangibles.
- On a YoY basis, Amortizatization of Intangibles climbed as much as 93.33% in 2023 and fell as far as 41.06% in 2023.
- A 5-year view of Amortizatization of Intangibles shows it stood at $123000.0 in 2022, then advanced by 4.07% to $128000.0 in 2023, then advanced by 15.62% to $148000.0 in 2024, then grew by 4.05% to $154000.0 in 2025, then retreated by 0.65% to $153000.0 in 2026.
- Business Quant data shows SLS's Amortizatization of Intangibles at $153000.0 in Q1 2026, $154000.0 in Q4 2025, and $147000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 13,267.00 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | SELLAS Life Sciences | 1.39 Bn | 1.39 Bn | - | 153,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 153,000.00 |
| Mar 31, 2026 | 153,000.00 |
| Dec 31, 2025 | 154,000.00 |
| Dec 31, 2025 | 154,000.00 |
| Sep 30, 2025 | 147,000.00 |
| Sep 30, 2025 | 147,000.00 |
| Jun 30, 2025 | 149,000.00 |
| Jun 30, 2025 | 149,000.00 |
| Mar 31, 2025 | 147,000.00 |
| Mar 31, 2025 | 147,000.00 |
| Dec 31, 2024 | 148,000.00 |
| Dec 31, 2024 | 148,000.00 |
| Sep 30, 2024 | 137,000.00 |
| Sep 30, 2024 | 137,000.00 |
| Jun 30, 2024 | 138,000.00 |
| Jun 30, 2024 | 138,000.00 |
| Mar 31, 2024 | 138,000.00 |
| Mar 31, 2024 | 138,000.00 |
| Dec 31, 2023 | 128,000.00 |
| Dec 31, 2023 | 128,000.00 |